Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.

导出 OA

翻译打印收藏纠错

作者： George C,Leef ^[1] ; Anne S,Hellkamp ^[2] ; Manesh R,Patel ^[2] ; Richard C,Becker ^[3] ; Scott D,Berkowitz ^[4] ; Günter,Breithardt ^[5] ; Jonathan L,Halperin ^[6] ; Graeme J,Hankey ^[7] ; Werner,Hacke ^[8] ; Christopher C,Nessel ^[9] ; Daniel E,Singer ^[10] ; Keith A A,Fox ^[11] ; Kenneth W,Mahaffey ^[1] ; Jonathan P,Piccini ^[12]

作者单位： Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, CA. ^[1] Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC. ^[2] University of Cincinnati College of Medicine, Cincinnati, OH. ^[3] Bayer HealthCare Pharmaceuticals, Parsippany, NJ. ^[4] Hospital of the University of Münster, Münster, Germany. ^[5] Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, NY. ^[6] School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia, Australia. ^[7] Ruprecht-Karls-University, Heidelberg, Germany. ^[8] Janssen Pharmaceutical Research and Development, Raritan, NJ. ^[9] Massachusetts General Hospital, and Harvard Medical School, Boston, MA. ^[10] University of Edinburgh and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom. ^[11] Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC jonathan.piccini@duke.edu. ^[12]

关键词 anticoagulation atrial fibrillation cardiac resynchronization therapy factor Xa inhibitor implantable cardioverter‐defibrillator pacemaker rivaroxaban warfarin